Q4 EPS Estimate for USANA Health Sciences Lifted by Analyst

USANA Health Sciences, Inc. (NYSE:USNA) – Equities researchers at Sidoti boosted their Q4 2026 earnings estimates for USANA Health Sciences in a research report issued to clients and investors on Wednesday, November 4th. Sidoti analyst A. Lebiedzinski now forecasts that the company will post earnings of $0.12 per share for the quarter, up from their previous estimate of $0.11. The consensus estimate for USANA Health Sciences’ current full-year earnings is $0.76 per share. Sidoti also issued estimates for USANA Health Sciences’ Q1 2027 earnings at $0.28 EPS, Q2 2027 earnings at $0.40 EPS, Q3 2027 earnings at $0.41 EPS and FY2027 earnings at $1.59 EPS.

USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.11 by ($0.22). USANA Health Sciences had a negative net margin of 2.34% and a positive return on equity of 3.55%. The business had revenue of $205.89 million for the quarter, compared to the consensus estimate of $217.42 million.

Several other research analysts have also issued reports on the stock. Weiss Ratings restated a “sell (d)” rating on shares of USANA Health Sciences in a research report on Monday, September 21st. Wall Street Zen downgraded USANA Health Sciences from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Zacks Research raised USANA Health Sciences from a “strong sell” rating to a “hold” rating in a research note on Monday, October 5th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Reduce”.

USANA Health Sciences Price Performance

USNA stock opened at $14.31 on Thursday. USANA Health Sciences has a 12 month low of $12.57 and a 12 month high of $23.59. The firm has a market cap of $264.45 million, a PE ratio of -12.44, a P/E/G ratio of 1.63 and a beta of 0.66. The firm has a 50 day simple moving average of $14.61 and a 200 day simple moving average of $18.03.

Hedge Funds Weigh In On USANA Health Sciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. State of Alaska Department of Revenue raised its stake in USANA Health Sciences by 79.3% during the 3rd quarter. State of Alaska Department of Revenue now owns 11,950 shares of the company’s stock valued at $172,000 after purchasing an additional 5,284 shares during the period. GAMMA Investing LLC lifted its holdings in shares of USANA Health Sciences by 689.4% in the third quarter. GAMMA Investing LLC now owns 2,763 shares of the company’s stock valued at $40,000 after purchasing an additional 2,413 shares in the last quarter. Hsbc Holdings PLC boosted its position in shares of USANA Health Sciences by 42.1% in the second quarter. Hsbc Holdings PLC now owns 31,960 shares of the company’s stock worth $673,000 after buying an additional 9,467 shares during the period. Nantahala Capital Management LLC acquired a new stake in shares of USANA Health Sciences in the second quarter worth $17,295,080. Finally, Empowered Funds LLC purchased a new position in shares of USANA Health Sciences during the second quarter valued at $1,500,000. Institutional investors and hedge funds own 54.25% of the company’s stock.

Key Headlines Impacting USANA Health Sciences

Here are the key news stories impacting USANA Health Sciences this week:

• Positive Sentiment: USANA’s BiOmega omega-3 supplement again earned ConsumerLab’s Seal of Approval, providing independent validation of its quality and purity. USANA BiOmega earns ConsumerLab Seal of Approval
• Neutral Sentiment: The quarterly net loss narrowed to $5.6 million from $6.5 million a year earlier; adjusted loss per share improved to $0.11 from $0.15. USANA reports third-quarter 2026 results
• Negative Sentiment: Net sales fell 4% year over year to $206 million, below the $217.4 million analyst consensus. Adjusted EBITDA also decreased to $12.1 million from $13.8 million. The adjusted loss of $0.11 per share missed expectations for $0.11 in earnings, a sharp disappointment despite the year-over-year improvement. USANA Q3 loss narrows, sales decline and outlook lowered
• Negative Sentiment: USANA lowered its FY2026 outlook, now expecting net sales to approach $900 million and adjusted EBITDA of approximately $77 million. The reduced forecast adds to concerns about the company’s declining sales and near-term earnings performance. USANA updates sales and adjusted EBITDA outlook

About USANA Health Sciences

USANA Health Sciences, Inc develops and sells nutritional supplements, healthy foods and personal-care products through a direct-selling business model. Its product portfolio includes vitamins and mineral supplements, meal-replacement and snack products, sports nutrition offerings, and skincare products marketed under the USANA and related brands.

Founded in 1992 by microbiologist and immunologist Myron W. Wentz, the company is headquartered in Salt Lake City, Utah. USANA distributes its products through a network of independent associates and preferred customers rather than primarily through traditional retail channels.

The company serves customers in markets across the Americas, Asia-Pacific and Europe, with a significant presence in countries including the United States, Canada, Australia, New Zealand, China, Hong Kong, Japan, South Korea, the Philippines, Singapore, Malaysia and Thailand.